ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer.

Autor: Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu., Zhao Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott AR; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy., Musteanu M; Experimental Oncology, Molecular Oncology Program, CNIO, Madrid, Spain.; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Complutense University of Madrid, Spain., Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 641-654. Date of Electronic Publication: 2021 Feb 03.

Rapid, sensitive assay for staphylococcal enterotoxin and a comparison of serological methods.

Autor: Silverman SJ, Knott AR, Howard M

Publikováno v: Applied microbiology [Appl Microbiol] 1968 Jul; Vol. 16 (7), pp. 1019-23.

Determination of thallium in biological material by flame spectrophotometry and atomic absorption.

Autor: Curry AS, Read JF, Knott AR

Publikováno v: The Analyst [Analyst] 1969 Sep; Vol. 94 (122), pp. 744-53.